Sanfang Tu

1.7k total citations
52 papers, 858 citations indexed

About

Sanfang Tu is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Sanfang Tu has authored 52 papers receiving a total of 858 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Hematology. Recurrent topics in Sanfang Tu's work include CAR-T cell therapy research (28 papers), Virus-based gene therapy research (10 papers) and Hematopoietic Stem Cell Transplantation (8 papers). Sanfang Tu is often cited by papers focused on CAR-T cell therapy research (28 papers), Virus-based gene therapy research (10 papers) and Hematopoietic Stem Cell Transplantation (8 papers). Sanfang Tu collaborates with scholars based in China, United States and Chile. Sanfang Tu's co-authors include Yuhua Li, Xuan Zhou, Meifang Li, Huilin Tu, Xinjie Xu, Xiaoqian Liang, Qihang Sun, Yanjie He, Yu Liu and Zitong Chen and has published in prestigious journals such as Blood, International Journal of Molecular Sciences and Frontiers in Immunology.

In The Last Decade

Sanfang Tu

51 papers receiving 854 citations

Peers

Countries citing papers authored by Sanfang Tu

Since Specialization

Citations

This map shows the geographic impact of Sanfang Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanfang Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanfang Tu more than expected).

Fields of papers citing papers by Sanfang Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanfang Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanfang Tu. The network helps show where Sanfang Tu may publish in the future.

Co-authorship network of co-authors of Sanfang Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Sanfang Tu. A scholar is included among the top collaborators of Sanfang Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanfang Tu. Sanfang Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia 2025 ·Chinese Medical Journal ·(unknown), (unknown), Shangjun Chen, Li Liu, Yuhua Li, Sanfang Tu, Hai Yi, Jian Zhou, Sanbin Wang, Ligen Liu, Jian Ge, Yongxian Hu, Xiaoqi Wang, Lu Wang, (unknown), Han Yao, Cheng Zhang, (unknown)	1
2	Epigenetic landscapes drive CAR-T cell kinetics and fate decisions: Bridging persistence and resistance 2025 ·Critical Reviews in Oncology/Hematology ·Kecheng Wang, (unknown), Yu Zeng, Chunyan Yue, Yue Zhuo, (unknown), Huifang Chen, Sanfang Tu	2
3	Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: A multi-center retropective study 2025 ·Chinese Medical Journal ·Lichao Liu, Yongxian Hu, (unknown), Yuhua Li, Sanfang Tu, Shangjun Chen, Hai Yi, (unknown), Jian Zhou, (unknown), Cheng Zhang, Xiaoqi Wang, Xi Zhang	0
4	Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma 2025 ·Chinese Medical Journal ·(unknown), (unknown), Xuan Zhou, (unknown), Bo Jin, Bo Wang, (unknown), Huifang Chen, Lijuan Zhou, Sanfang Tu, Yuhua Li	1
5	Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study 2024 ·Blood ·Ingrid Glimelius, Won Seog Kim, Ewa Paszkiewicz‐Kozik, (unknown), Reid W. Merryman, Cláudia Moreira, Sanfang Tu, Yixin Ren, (unknown), Uzor C. Ogbu, Pier Luigi Zinzani	1
6	Construction and validation of a regulatory T cells-based classification of renal cell carcinoma: an integrated bioinformatic analysis and clinical cohort study 2024 ·Cellular Oncology ·(unknown), Yifan Liu, Bing-Nan Lu, (unknown), Lei Wang, Keqin Dong, (unknown), (unknown), (unknown), Sanfang Tu, (unknown), (unknown), Runzhi Huang, (unknown), Guofeng Xu, Xiuwu Pan, Xingang Cui	2
7	Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion 2023 ·Human Cell ·Liang Zhao, (unknown), Xuan Zhou, Jilong Yang, Sanfang Tu, Yanjie He, Lijuan Zhou, Yuhua Li	3
8	Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML) 2023 ·Blood ·Hongyan Tong, Sujun Gao, Wei Yang, Junmin Li, Qingsong Yin, Xingli Zhao, Xiaojing Yan, Sanfang Tu, Fei Li, (unknown), Rong‐Hua Hu, Shaoyuan Wang, Zheng Dong, Yixuan Yang, (unknown), (unknown), Wenzhi Tian, Zhijian Xiao, Jianxiang Wang	4
9	Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies 2022 ·Frontiers in Immunology ·Xinyi Xiao, Yazhuo Wang, (unknown), Yufei Yang, Xinyu Wang, Xin Xin, Sanfang Tu, Yuhua Li	22
10	Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial 2022 ·BMC Medicine ·Xin Xu, Zhiping Fan, Yu Wang, Fen Huang, Yajing Xu, Jing Sun, (unknown), Lan Deng, Xudong Li, Xinquan Liang, Xiaodan Luo, Pengcheng Shi, Hui Liu, Yan Chen, Sanfang Tu, Xiao‐Jun Huang, Qifa Liu, Li Xuan	4
11	Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis 2022 ·Critical Reviews in Oncology/Hematology ·Sifei Chen, Yuchen Zhang, (unknown), (unknown), Yu Wang, (unknown), Yuhua Li, Sanfang Tu	15
12	Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis 2021 ·Frontiers in Oncology ·Xinjie Xu, Sifei Chen, (unknown), Xinyi Xiao, Shengkang Huang, (unknown), Yuhua Li, Sanfang Tu	13
13	Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation 2020 ·Acta Pharmaceutica Sinica B ·Liang Jiang, Yuting Wang, Qian Li, Zhengchao Tu, (unknown), Sanfang Tu, Zhang Zhang, Ke Ding, Xiaoyun Lu	27
14	Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas 2020 ·Frontiers in Immunology ·Xuan Zhou, Sanfang Tu, Chunsheng Wang, Rui Huang, Lan Deng, Chaoyang Song, Chunyan Yue, Yanjie He, Jilong Yang, Liang Zhao, (unknown), Meifang Li, Weijun Zhou, Jingwen Du, (unknown), (unknown), (unknown), Cheng Jiao, Yuchen Liu, Lung‐Ji Chang, Yuhua Li	41
15	CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma 2019 ·Frontiers in Oncology ·Sanfang Tu, Xuan Zhou, (unknown), Rui Huang, Chunyan Yue, Yanjie He, Meifang Li, Yiran Chen, (unknown), Lung‐Ji Chang, Yuhua Li	55
16	Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies 2019 ·Frontiers in Immunology ·Xinjie Xu, Qihang Sun, Xiaoqian Liang, Zitong Chen, Xiaoli Zhang, Xuan Zhou, Meifang Li, Huilin Tu, Yu Liu, Sanfang Tu, Yuhua Li	219
17	A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation 2019 ·Journal of Experimental & Clinical Cancer Research ·Meifang Li, Jilong Yang, (unknown), Sanfang Tu, Xuan Zhou, Ze Tan, Weijun Zhou, Yanjie He, Yuhua Li	12
18	Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Posttransplant Lymphopoliferative Disorder 2016 ·The American Journal of the Medical Sciences ·Sanfang Tu, (unknown), Xianbo Wu, Yuhua Li, Chaoyang Song	1
19	Overexpression of EPS8 is associated with poor prognosis in patients with acute lymphoblastic leukemia 2015 ·Leukemia Research ·(unknown), Liang Zhao, Meirong Wu, Qi Wen, Lan Deng, Chaoyang Song, Bingyi Wu, Sanfang Tu, Rui Huang, Yuhua Li	15
20	Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study 2013 ·Journal of Hematology & Oncology ·Hui Liu, Xiao Zhai, (unknown), Jing Sun, Yang Xiao, Danian Nie, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Sanfang Tu, Yonghua Li, Xutao Guo, Guopan Yu, Qifa Liu	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact